Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

a technology azaoxoindole, which is applied in the field of new azaoxoindole for the treatment and prophylaxis of respiratory syncytial virus infection, can solve the problems of limiting the ability of individuals to transmit respiratory syncytial virus within households, nursing homes and hospital settings to other hosts at high risk of complications, and bronchiolitis and pneumonia

Inactive Publication Date: 2018-03-15
F HOFFMANN LA ROCHE INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention introduces new compounds (Formula I) and their manufacturing process. Additionally, the invention provides pharmaceutical products containing these compounds and the use of these compounds for treating or preventing RSV infection.

Problems solved by technology

Severe case of RSV infection often leads to bronchiolitis and pneumonia, which requires hospitalization.
A severe infection at young age may lead to recurrent wheezing and asthma.
It is also expected to limit the ability of individuals to transmit RSV within households, nursing homes and the hospital setting to other hosts potentially at high risk of complications.
There is no RSV vaccine available for human use, despite of many attempts in subunit vaccine and live-attenuated vaccine approaches.
However, it is rarely used clinically, due to limited efficacy and potential side effects.
Unfortunately, palivizumab is not effective in the treatment of established RSV infection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
  • Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
  • Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Examples

Experimental program
Comparison scheme
Effect test

example 1

5-{5-Chloro-2-[(2′-oxospiro[cyclopropane-1,3′-pyrrolo[2,3-c]pyridin]-1′(2′H)-yl)methyl]-1H-benzimidazol-1-yl}pyridine-2-carbonitrile

[0171]Step 1: Preparation of 5-nitropyridine-2-carbonitrile

[0172]A mixture of 2-bromo-5-nitropyridine (12.0 g, 59.1 mmol, CAS No.: 4487-59-6) and copper (I) cyanide (7.94 g, 88.7 mmol) in N,N-dimethylformamide (50 mL) was heated under reflux for 16 hours. After being cooled down to room temperature, the reaction mixture was poured into water and then extracted with ethyl acetate (100 mL×3). The combined organic layer was washed with brine, and then dried over sodium sulfate and filtered. The filtrate was concentrated in vacuo to afford 8.0 g of 5-nitropyridine-2-carbonitrile (yield was 90.8%).

[0173]Step 2: Preparation of 5-aminopyridine-2-carbonitrile

[0174]To a solution of 5-nitropyridine-2-carbonitrile (7.0 g, 46.9 mmol) in methanol (150 mL) was added 10% palladium on carbon (2.0 g) and carbamic acid (7.0 g, 115 mmol). After being heated under reflux f...

example 2-1

1′-({5-Chloro-1-[2-(methylsufonyl)pyridin-4-yl]-1H-benzimidazol-2-yl}methyl)spiro[cyclopropane-1,3′-pyrrolo[2,3-c]pyridin]-2′(1′H)-one

[0195]Step 1: Preparation of 2,4-bis(methylsulfonyl)pyridine

[0196]A mixture of 2,4-dichloropyridine (1.68 g, 11.0 mmol, CAS No.: 26452-80-2), sodium methanesulfinate (3.96 g, 33.0 mmol, 85% purity, CAS No.: 20277-69-4) and tetrabutylammonium chloride (917 mg, 3.3 mmol) in N,N-dimethylformamide (10 mL) was heated at 150° C. under microwave irradiation for 1 hour. The resulting mixture was then stirred with water (20 mL). The precipitate was collected by filtration to afford 1.59 g of 2,4-bis(methylsulfonyl)pyridine as a light pale solid (yield was 61.5%).

[0197]Step 2: Preparation of N-(4-chloro-2-nitrophenyl)-2-(methylsulfonyl)pyridin-4-amine

[0198]A mixture of 2,4-bis(methylsulfonyl)pyridine (1.41 g, 6.0 mmol), 4-chloro-2-nitroaniline (1.03 g, 6.0 mmol, CAS No.: 89-63-4) and potassium carbonate (828 mg, 6.0 mmol) in N,N-dimethylformamide (10 mL) was he...

example 2-2

1′-({5-Chloro-1-[4-(ethylsulfonyl)pyridin-2-yl]-1H-benzimidazol-2-yl}methyl)spiro[cyclopropane-1,3′-pyrrolo[2,3-c]pyridin]-2′(1′H)-one

[0205]The title compound was prepared in analogy to Example 2-1 by using sodium ethanesulfinate (CAS No.:20035-59-4) instead of sodium methanesulfinate.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides novel compounds having the general formula:wherein R1, R2, R3, R4, R5, W and X are as described herein, compositions including the compounds and methods of using the compounds.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of International Application No. PCT / EP2014 / 067197 having an international filing date of Aug. 12, 2014, the entire content of which is hereby incorporated herein by reference, and which claims the benefits of PCT / CN2013 / 081563 having a filing date of Aug. 15, 2013.[0002]The present invention relates to organic compounds useful for therapy and / or prophylaxis in a mammal, and in particular to respiratory syncytial virus (RSV) inhibitors useful for treating RSV infection.FIELD OF THE INVENTION[0003]Respiratory Syncytial Virus (RSV) belongs to the family of Paramyxoviridae, subfamily of Pneumovirinae. The human RSV is a major cause of acute upper and lower respiratory tract infection in infants and children. Almost all children are infected by RSV at least once by age of three. Natural human immunity against RSV is incomplete. In normal adults and elder children, RSV infection is mainly associated with uppe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): C07D471/04C07D401/06C07D403/06
CPCC07D471/04C07D401/06C07D403/06A61P31/12A61P31/14
InventorWANG, LISHAYUN, HONGYINGZHANG, WEIXINGZHENG, XIUFANG
OwnerF HOFFMANN LA ROCHE INC